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ABSTRACT 
Objective: The objective of this work was to identify the instruments used to assess 
polymyalgia rheumatica (PMR) in published studies.  
Methods: A systematic literature review of Clinical Trials and longitudinal observational 
studies related with PMR, published from 1970 to 2014, was carried out. All outcomes and 
assessment instruments used were extracted and categorised according to core areas and 
domains, as defined by OMERACT 11, filter 2.0. 
Results: 35 articles (3,221 patients) were included: 12 RCTs; 3 non-randomised trials; and 20 
observational studies. More than 20 domains were identified, measured by 29 different 
instruments. The most frequently used measures were pain, morning stiffness, patient and 
physician global assessment, erythrocyte sedimentation rate and C-reactive protein. The 
definition of outcomes varies considerably between studies. 
Conclusion: The outcome measures and instruments used in PMR are numerous and 
diversely defined. The establishment of a core set of validated and standardized outcome 
measurements is needed. 
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INTRODUCTION 
PMR is an inflammatory disease with a lifetime risk estimated at 2.4% for women 
and 1.7% for men (1) and a peak incidence after 60 years of age. The diagnosis of PMR 
relies on clinical and laboratory manifestations, supported by a rapid, favourable response to 
glucocorticoid therapy at medium doses (15-20 mg/day of prednisone or equivalent). When 
untreated, PMR can cause profound disability. Glucocorticoid therapy remains the gold 
standard therapy for PMR and is usually efficacious. However, the potential toxicity of long-
term glucocorticoid therapy (2) imposes the need to search for safer alternatives.   
Future research in PMR requires the use of valid and reliable outcome measures that 
encompass the relevant scope of disease manifestations. A variety of outcomes have been 
used to assess disease activity, including clinical features (pain and morning stiffness), 
ultrasonography parameters and laboratory measures such as Erythrocyte Sedimentation 
Rate (ESR), C-Reactive Protein (CRP) and interleukin-6 (IL-6) levels. Composite scores of 
disease activity (3) and definitions of good response, remission and relapse have been 
proposed (3-6). However, these measures have not yet been extensively validated in PMR 
and do not incorporate patient viewpoints. 
The Outcome Measures in Rheumatology (OMERACT) initiative aims to develop 
core sets of outcome measures capable of providing consistent estimates of the benefits of 
interventions for each given condition in clinical trials (7). According to the OMERACT 11 
filter 2.0, such core sets should include at least one Domain from each Core Area.  Four Core 
Areas, broad aspects of a health condition, are defined: three encompass the “Impact of 
Health conditions” – Life Impact, Resource Use, and Death, and a fourth Core Area 
encompasses Pathophysiological Manifestations (8, 9). This filter also considers Domains, 
as sub-specifications within one Area (9, 10). In order to be included in a core set, a domain 
should be measurable by truthful, discriminative and feasible instruments (9, 11).  
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The OMERACT PMR Working Group was formed to define a core set of outcome 
measures to be used in future clinical research in PMR. With this systematic literature 
review we aim to supply this endeavour with objective information on the outcome measures 
currently used to assess PMR disease activity and response to treatment.  
METHODS 
Search strategy: The literature search was performed in MEDLINE, CINAHL, Science 
Citation Index of Web of Sciences, Cochrane Library (Cochrane Central Register of 
Controlled Trials CENTRAL and Cochrane Database of Systematic Reviews CDSR).  The 
research strategy was based on the following Key words:  ("Polymyalgia 
Rheumatica"[MeSH]), and covered material published from January 1
st
 1970 to June 30
th
 
2014.  
Inclusion Criteria: Studies were included if they: 1) used published classification criteria to 
select patients; 2) were written in English, French, Portuguese or Spanish languages; 3) 
followed a design of either Clinical Trial or longitudinal observational study, and 4) were 
available in full text. Studies which included an heterogeneous patient sample and published 
data that did not allow differentiating PMR subjects from other diseases (eg. Giant Cell 
Arteritis or late onset Rheumatoid Arthritis) were excluded.   
Study selection: Titles, abstracts and full reports of articles identified were systematically and 
independently screened by two authors (CD and RF) with regards to inclusion and exclusion 
criteria. In the first step, selection was based on titles and abstracts. Full reports of articles 
selected on this phase were evaluated (second step) to select the papers to include in this 
systematic review. Disagreements regarding selection of one article were discussed between 
both reviewers until consensus was reached. Persistent disagreements were resolved by a third 
evaluator (JAPS).  
Data extraction: During data extraction, special attention was given to the “Patients and 
Methods” and “Results” sections of each article. All data were extracted using a standardized 
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template designed for this review, which had been piloted and improved, which included: 
study design, sample size, follow-up period, outcome measures used and the method of 
assessment.  
Each outcome was characterized according with OMERACT Filter 2.0 considering Core 
Areas (Pathophysiological Manifestations, Life Impact, Death, Resource Use) and Domains 
(10). 
 
RESULTS  
The results of the literature search and selection of papers is presented in Figure 1. The 
electronic search strategy yielded 868 articles, 43 of which were selected, on the basis of title 
and abstract, for further assessment/detailed review. At the end, 35 studies (12-46) met the 
inclusion criteria for this systematic review (Figure 1). The agreement between the two 
reviewers was 96.6 % and 100% on the first and second step of articles’ selection, 
respectively.  
(Place Figure 1 here) 
Included studies 
Table 1 shows the study design characteristics of the included articles. Twelve of the included 
studies are RCTs of medication, controlled against either placebo or conventional PMR 
treatment (12-23). Three are non-randomized interventional studies or without clear 
information about randomization (24-26). Longitudinal observational studies represent more 
than half of the selected articles (20 of 35) (27-46). One of these observational studies (36) is 
a long-term follow-up of one RCT already included (20). The study size ranged from 4 (24) to 
781 subjects (32, 41), with follow-up periods varying between 14 days (22) to 34 years (32). 
All studies included a majority of females and patients older than 50 years, which is in 
agreement with classical PMR features (47-50). 
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(Place Table 1 here) 
The studies identified in this literature review include outcomes and instruments pertinent to 
all Core Areas defined by OMERACT, except Resource Use. The Core Area most represented 
is “Pathophysiological Manifestations” which included a total of six domains, followed by 
“Life Impact” with five domains (Table 2).  
(Place table 2 here) 
Pain 
Pain was used as an outcome in 17 studies (12-16, 18, 19, 22, 25, 34, 36, 39, 40, 43-46) A 
Visual Analogue Scale (VAS) was commonly used to quantify pain, usually as a 0-10 cm 
scale (11 studies).  In three of them (12, 14, 16),  pain was graded using an ordinal scale form 
“0” to “3”. 
Most published reports do not provide a clear definition of the pain being assessed. The 
description of pain localization varies: “shoulder and pelvic girdle pain” (15), “proximal pain” 
(34), “proximal muscle pain” (14, 16), or “joint or muscle pain” (13). Matteson and colleagues 
evaluated pain considering different locations as shoulder, limbs and global (44). None of the 
published reports specified the period of time under evaluation when asking the patients about 
their “pain”. 
 
Morning Stiffness 
Stiffness, more commonly morning stiffness, was considered in almost all the included 
studies (13-16, 18-22, 24-28, 30, 33-38, 40, 43-46). It was evaluated as an independent 
outcome in 11 studies (13-16, 18, 19, 25, 27, 34, 40, 44), and was included as parameter in 
composite disease activity scores or in the definition of relapse/recurrence/remission in an 
additional 15 studies (19, 20, 22, 24, 26, 28, 33, 35-38, 43-46). 
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Morning stiffness was measured in terms of duration (“minutes”) in the majority of the 
studies. In one RCT (18), morning stiffness duration was reported in one study through a 4-
point scale (1= <30 min.; 2= 30-60 min.; 3= 60-120 min.; and 4= >120 min.) In two studies, 
stiffness was graded from 0 to 3, where “0” means no symptoms, but it is unclear whether 
severity, duration or both were being assessed (14, 16). No information is given to the 
meaning of the other values in the scale. Only Weyand and colleagues (27) evaluated the 
severity of morning stiffness using a 0-10 cm VAS. Only one RCT (13) and one observational 
study (27) gave precise information about the time interval under evaluation (“average of last 
week”).   
 
Patient and Physician Global assessment 
Patient Global Assessment (PGA) of disease activity was measured in nine studies (13, 19, 
22, 25, 27, 33, 35, 38, 46), always as a 0-10 cm VAS except in two studies (13, 27), where a 
5-point ordinal scale was used.  
Physician Global Assessment (PhGA) was used in 14 studies (12, 13, 19, 22, 25, 27, 33, 35, 
36, 38, 43-46), twelve of them as a 0-10 cm VAS and two (13, 27) as 5-point ordinal scales.  
In 9 studies (22, 25, 35, 36, 38, 43-46) both PGA and PhGA were included as a parameter 
within a pre-defined composite disease activity score.  
Two instruments were employed by a single study (33): 1. a PGA of General Health and 2. a 
Patient Satisfaction with Disease Status (PATSAT) (classification of disease state according 
to the Austrian school mark system - 1=excellent, 2=good, 3=average, 4=moderate, 
5=unsatisfactory).  
 
Function and Quality of Life (QoL) 
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Function was assessed in five observational studies (34, 36, 38, 44, 46), one open label trial 
(25) and three RCTs (21-23). In all studies, function was assessed through the generic 
instrument Health Assessment Questionnaire (HAQ) (51).  
Health-related QoL was considered in two large observational studies (34, 44) and was 
assessed through the generic tool Medical Outcome Survey-Short Form (MOS-SF 36) (52). In 
a single observational study (46), QoL during the past month was assessed using a 0-100 mm 
VAS, where 0 means normal and 100 the worst QoL.  
 
Other Clinical outcomes: Elevation of upper limbs was considered as an outcome in some 
studies (22, 25, 33, 35, 43, 45, 46), always as a component of a composite disease activity 
score. Upper limb elevation was measured on a 0-3 scale with the following levels: 3 - no 
upper limb elevation; 2 - elevation bellow shoulder level (<90º); 1 - elevation at shoulder 
level (90º); and 0 - elevation above shoulder level (>90º). Muscle function (23) (hand grip 
strength and jump test), chair stand test (23), ten meters walking (23), and time to onset of 
fatigue (hours) (13) were used as outcomes in one single study each. Intensity of fatigue 
reported by the patient, using a 0-100 mm VAS, was assessed in a single study (44). 
 
ESR and CRP 
ESR (12-19, 21, 22, 24-28, 30, 31, 33-40, 43-46) and CRP (12, 13, 15, 17, 19, 21, 23-26, 28, 
30, 31, 33-38, 40, 43-46) were used in the assessment of disease activity by most but not all 
RCT and observational studies.   
 
Other Laboratory measures  
Other laboratory outcome measures used in some observational and clinical trials include 
serum fibrinogen (12, 15, 16, 45, 46) and IL-6 levels (19, 22, 24, 27, 30, 31, 37), mainly as 
experimental evaluations.  
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Ultrasonography  
Ultrasonography was used in three prospective observational studies (38, 40, 44) and in one 
open label trial (25). Different studies used different evaluation protocols, there being no 
formal proposal for the standardization of US evaluation of response to therapy in PMR. 
Jiménez-Palop and colleagues considered the evaluation of intra-articular synovitis at the 
shoulder and hip, tenosynovitis, and bursitis in the shoulder. This study demonstrated good 
inter and intra-observer reliability (0.96 and 0.99 respectively) but no statistically significant 
correlation was found with clinical and laboratory parameters of disease activity (40). 
 
Composite Measures 
Most of the studies integrated the individual outcome measures into composite indices, 
considered as response/relapse criteria or activity scores. This is summarized in table 3. Most 
of them defined relapse or recurrence as the observation of new symptoms, increase of ESR 
(usually >30 mm), or increase of CRP (higher than 0.5 mg/dl or 1 mg/dl), after remission has 
been achieved, in patients receiving glucocorticoids (GCs) or after discontinuation of GCs, 
respectively.  Proposed Response Criteria include an improvement of symptoms and 
reduction/normalization of inflammatory parameters (ESR and CRP). In 2003, the European 
Collaborating Polymyalgia Rheumatica Group proposed a core set of response criteria. These 
EULAR response criteria comprise an improvement in VAS pain (obligatory) and at least 3 of 
the following 4 items: CRP (mg/l) or ESR (mm/1st h), Morning stiffness (min), Elevation of 
upper limbs (0–3), and VAS PhGA (4).  However, there is considerable discrepancy in the 
definition of “improvement” and in the duration of improvement required to define 
“response”. 
One of the most common composite disease activity scores used was the Polymyalgia 
Rheumatica Activity Score (PMR-AS), developed by Leeb and Bird (6) and defined as 
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PMR-AS = CRP(mg/dl) + E(0-3) + 0.1XMST(min) + VASp(0-10) + VASph(0-10)
1
 
The PMR-AS score, showed a good correlation with other outcome measures, namely with 
VAS Patient Global assessment (r=0.76) and ESR (r=0.32) (6, 33). Given that CRP is a 
component of PMR-AS it is not surprising that the composite score correlated with ESR, 
which is closely associated with CRP. Similarly, another component of PMR-AS is the 
patient pain VAS, and patient global VAS is usually strongly correlated with pain VAS.  
PMR-AS also showed a very good internal consistency in two different cohorts (Cronbach 
alfa of 0.90 and 0.88) (6) and demonstrated reliability (3, 33, 53).  
 
(Place Table 3 here) 
 
Glucocorticoid Therapy 
The characterization of the GC treatment regime employed is extremely variable. Only a few 
studies included the cumulative dose of GCs (21, 27, 36), the minimum dose required (13, 17, 
21), the duration of therapy (21), or the percentage of discontinuation of steroids after a 
specified duration of follow up (13, 20, 21, 36). 
 
Adverse Events 
The incidence and characterization of adverse events related to interventions were described 
in the majority of the clinical trials (15-25) and in the long-term follow-up study of patients 
treated with methotrexate (36). None of the studies performed a systematic and structured 
evaluation of safety. 
Some observational studies were designed to assess specific adverse events related to GCs, 
such as vertebral fractures (39, 42), bone mineral content (16, 42), cardiovascular and 
cerebrovascular events (32, 42). One study described mortality and its causes (29). The 
                                            
1
 CRP: C-Reactive Protein; E: Elevation of upper limbs; MST: Morning Stiffness Time; VAS: Visual Analogue 
Scale; p: patient; ph: physician. 
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methods used to elicit adverse effects in observational studies was variable but death registries 
and patient files were the most common sources of information.  
 
DISCUSSION  
This systematic literature review highlights a remarkable variability in the assessment of PMR 
in research settings.  
Patient Reported Outcomes (PRO) are the most commonly studied outcomes and were 
assessed in almost all of the studies included in this review. Fatigue, however, was evaluated 
in two studies only. Function and QoL were evaluated in less than 10% of the studies, in spite 
of the importance to patients of these (54).  
The instruments used to measure PROs in the selected articles were very heterogeneous. Also, 
there was, in general, a poor definition of what is actually being measured (e.g. concerning 
morning stiffness: is the question referring to the girdles, the hands or elsewhere? At what 
time of the day? What is the time period being assessed? Are we measuring duration, severity 
or both?).  
There are no studies addressing the relative importance of each outcome from the patients’ 
perspective. During the “OMERACT 11” Meeting (North Carolina, USA, May 2012) data 
from a preliminary, “scoping” consultation exercise involving 104 PMR patients from three 
centres from the UK and one from Belgium was presented by the PMR-SIG Group. In this 
study, patients were invited to express their concerns regarding disease and treatment. 
Symptoms and “impairment” were clearly important to patients, with pain, stiffness, fatigue, 
and sleep disturbance being mentioned very often. Physical activity and treatment aspects like 
glucocorticoid-related adverse effects were also considered important (54). It is important that 
patients’ concerns and wishes are incorporated into any core outcome set.  
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Outcomes assessed by physicians rather than patients were less heterogeneous. Physician 
reported outcomes were used less frequently than PRO, with PhGA (as a 0-10cm VAS) being 
the most commonly used. Given the discrepancies between patient’ and physicians’ 
evaluations that have been found in several diseases (55-57), it is generally considered that 
both PRO and physician reported outcomes should be included to capture the burden of 
disease.  
All selected articles reported either ESR or CRP, except in studies designed to evaluate 
specific adverse events (29, 32, 41, 42).  Other laboratory parameters, such as IL-6 and 
fibrinogen, or ultrasonography have been considered so far as “experimental” outcomes.  
Disease activity scores or definitions of Remission, incorporating both physician- and patient- 
reported outcomes, are well-established in other Rheumatic Diseases and may prove useful 
also in PMR. The concepts of remission/relapse/recurrence are not consistently defined for 
PMR. A composite score of disease activity, the PMR-AS, was developed by Leeb and 
colleagues in 2007 (33) and has been used in approximately 40% of the selected articles 
published after 2007.  
We recognize some strengths and limitations to our study. We used the most important 
databases of medical research articles, considered other languages beside English and 
scrutinized a long period of time. The lack of evaluation of the quality of papers may be seen 
as a limitation but we believe this was the most adequate strategy to serve the primary goal of 
identifying all possible outcomes under current use. As a limitation, we have not searched 
Conference abstracts or contacted the authors in order to enlarge our scope. By including only 
longitudinal observational studies and clinical trials with PMR population, we may have lost 
some outcomes used in cross-sectional studies or in larger studies of rheumatic diseases. We 
did not perform any psychometric analysis of each instrument, as this was outside the 
intended scope of this work.  
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CONCLUSION 
Our study revealed that a great heterogeneity currently exists in the assessment of PMR. Most 
instruments have been insufficiently validated according to the OMERACT Filter and the 
patients’ perspective may not always have been fully covered. These data suggest that further 
work is needed to define and validate relevant outcome measures for assessment of PMR in 
order to promote clinical research in this field and enhance comparability of studies. Core 
areas and domains need to be defined according with the OMERACT procedures. Evaluation 
instruments capable of satisfying the properties required by OMERACT Filter 2.0 need to be 
developed, including validity, reliability, feasibility, and responsiveness.  
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Figure 1: Flow chart of the search and selection process. 
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year 
First Author and 
reference 
Study design/ Protocol Intervention 
Sample 
size 
PMR Definition/ 
stage of disease 
Follow-up 
Randomized clinical trials 
1987 Lund (12) 
RCT, double blind, cross 
over (after a single blind 
parallel 3 arms) 
Deflazacort vs Prednisone, 
weigh ratios of 1:1,2; 1: 
1,5 and 1:1,8 
41 
Bird 
Maintenance phase 
 
 
12 weeks  
1995 Littman (13) 
RCT, multicentre, placebo 
controlled 
Tenidap 120 mg/day+ 
PDN 10 mg/day vs 
Placebo+PDN 10mg/Day 
32 
Study Definition 
Stable disease  
15 weeks 
1995 Krogsgaard (14) 
RCT, double blind, 
controlled 
Deflazacort vs 
prednisolone 
30 
Bird 
New diagnoses 
12 months 
1995 Di Munno (15) 
RCT, double blind, cross-
over 
Deflazacort vs 
methylprednisone 
29 
Study definition 
New diagnoses 
12 weeks 
1996 
Krogsgaard (16) 
 
RCT, double blind, 
controlled 
Deflazacort vs 
prednisolone 
30 
 
Bird 
New diagnoses 
12 months 
1996 Ferraccioli (17) RCT, Open. 
Prednisone 15 mg vs 
Prednisone 25mg+ 
Metothrexate 10mg/wk 
24 
Study definition 
New diagnoses 
 
12  months 
1998 Dasgupta (18) 
RCT, double blind, 
multicentre 
 
Methylprednisone  depot 
VS prednisolone po 
60 
Study definition 
New diagnoses 
96 weeks 
2000 Salvarani (19) 
RCT, double blind 
placebo controlled 
 
Shoulder injection of 40 
mg of methylprednisone 
20 
Healey 
New diagnoses 
7 months 
2004 Caporalli (20) 
RCT, multicentre, double-
blind, placebo controlled 
Methotrexate 10 mg/wk+ 
GC vs Placebo+ GC 
72 
Chuang  
New diagnoses 
 
18  months 
2007 Salvarani (21) 
RCT, multicentre, double 
blind, placebo controlled 
Infliximab 3mg/kg vs 
Placebo 
51 
Healey 
 New diagnoses 
52 weeks 
2010 Kreiner (22) 
RCT, double blind, 
placebo controlled. 
Etanercept 25 mg 2/wk vs 
Placebo 
20 
Chuang,  
New diagnoses 
2 weeks 
2011 Björman (23) 
RCT, cross-over, double 
blind 
Casein vs protein-enriched 
dairy product 
60 
Rheumatologist 
definition* 
20 weeks 
Non-randomized clinical trials 
2003 Salvarani (24) 
Open, pilot, uncontrolled 
study 
Infliximab + Prednisone 4 
Healey Longstanding 
disease 
49 weeks 
2007 Catanoso (25) 
Clinical trial, open, 
uncontrolled 
Etanercept 25mg twice/wk, 
24 wk 
6 
Healey 
Relapsing/ 
longstanding 
36 weeks 
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2011 Cimmino (26) 
Clinical trial not 
randomized, uncontrolled 
Prednisone 12,5mg/id 60 
Bird  
New diagnoses 
6 months 
Observational studies 
1999 Weyand (27) 
Prospective 
observational study 
NA 30 
Study definition 
New diagnoses 
12-33 
months 
2000 Cantini (28) 
Prospective 
observational study 
NA 177 
Healey 
New diagnoses 
5 years 
2003 Myklebust (29) 
Prospective 
observational study 
Gender-age matched 
controls  
NA 65 
Bird or Harlim 
Any stage 
1987-1997 
2005 Salvarani (30) 
Prospective 
observational study 
NA 94 
Healey 
New diagnoses 
24 months 
2006 Boiardi (31) 
Prospective 
observational study 
NA 112 
Healey  
New diagnoses 
24  months 
2007 Kremers (32) 
Prospective 
observational study 
NA 364 
Chuand and Hunder, 
New diagnoses 
1970-2004 
2007 Leeb (33) 
Prospective 
observational study 
NA 39 
Bird 
 
18 months 
2007 Hutchings (34) 
Prospective 
observational, 
multicentre study 
NA 129 
Hazelman 
New diagnoses 
 
12  months 
2008 Binard (35) 
Prospective 
observational study 
NA 89 
Rheumatologist 
definition* 
Not defined 
2008 Cimmino (36) 
Long term follow-up of  
RCT (20) 
Methotrexate 10 mg/wk 57 
Chuang  
New diagnoses 
 
5 years 
2008 Pulsatelli (37) 
Prospective 
observational study 
NA 93 
Healey 
New diagnoses 
24 months 
2009 Macchioni (38) 
Prospective 
observational study 
NA 57 
Healy 
New diagnoses 
41 months 
2010 Calvo (39) Case Cohort study NA 20 
ACR criteria (Chuang 
and Healey) 
New diagnoses 
12 months 
2010 
Jiménez-Palop 
(40) 
Prospective 
observational, 
multicentre study 
NA 59 
Study definition 
New diagnoses 
12 weeks 
2011 Kang (41) Prospective NA 781 Rheumatologist 3 years 
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Table 1: Characterization of the studies included in the analysis.  
NA: Not Applicable; RCT: Randomized Controlled Trial.* autonomous clinical diagnoses by 
attending rheumatologist.    
observational study definition* 
New onset cases 
2012 Mazzantini (42) 
Retrospective 
Observational study 
NA 222 
Bird  
Longstanding disease 
Not defined 
2012 Cleuziou (43) 
Prospective 
observational study 
NA 89 
Rheumatologist 
definition* 
Not defined 
2012 Matteson (44) 
Prospective 
observational study 
NA 85 
ACR/EULAR  
New diagnoses 
6 months 
2013 McCarthy (45) 
Prospective 
observational study 
NA 60 
Jones & Hazleman 
New diagnoses 
6 weeks 
2014 McCarthy (46) 
Prospective 
observational study 
NA 60 
Jones & Hazleman 
New diagnoses 
6 weeks 
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Core Area Domain 
N. of 
studies 
Instrument 
N. of studies using the 
instrument 
Pathophysiological 
 
Laboratory markers 
 
 
 
30 
 
 
ESR 29 
CRP 23 
IL6, Fibrinogen 12 
Ultrasonography 4 Girdles US evaluation 4 
Pain 17 
VAS 0-10 cm 11 
VAS 0-100 mm 2 
VAS 0-32 1 
Grade 0-3 3 
Morning stiffness 26 
Duration (min) 11 
Grade 4 
Severity (VAS 0-10) 1 
As a parameter of compositum measure or 
definition 
15 
Life impact 
PGA 9 
VAS 0-10 7 
5 point-scale 2 
PhGA 14 
VAS 0-10 12 
5 point scale 2 
PATSAT 1 Range 1-5 1 
Function 5 HAQ 5 
Quality of life 2 
MOS-SF36 1 
VAS 0-100 1 
Death Mortality 1 SMR 1 
Resource - 0 - - 
Composite 
measures 
Disease activity 8 PMR-AS 8 
Remission 6 Own definition 6 
Recurrence/Relapse 8 Own definition 8 
Contextual factors 
Adverse events 
Side effects 14 
General 12 
Bone mineral content 2 
Vertebral fracture 2 
Glucocorticoid 
therapy 
6 
Minimal dose 2 
Cumulative dose 3 
Discontinuation 4 
Vascular disease 3 AMI, HF, CVA, PVD 3 
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Table 2: Health Areas, Domains and Instruments reported in the 35 selected articles. 
AMI: Acute Myocardial Infarction, CVA: Cerebrovascular Accident, HAQ: Health 
Assessment Questionnaire; HF: Heart Failure, PMR-AS: Polymyalgia Rheumatica Activity 
Score; PVD: Peripheral Vascular Disease, SMR: Standardized Mortality Rate; VAS: Visual 
Analogue Scale.  
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Year Study Good Response Remission 
Relapse (under GC´s) or 
Recurrence (after GC´s) 
Activity 
Score 
1995 
Di Munno 
(15) 
At the end of  2 weeks of 
GC´s: >50 % of pain, 
morning stiffness, ESR and 
CRP improvement 
 
At the end of 12 weeks of 
GC´s: >80 % of 
improvement in pain and 
morning stiffness; ESR and 
CRP normal 
NA NA NA 
2000 Cantini (28) NA NA 
Joint signs or symptoms 
ESR>30 mm/hr 
Restart or increase GCs 
NA 
2000 
Salvarani 
(19) 
>70% improvement in Pain-
VAS, Patient and Physical 
Global Assessment, and 
morning stiffness 
NA NA NA 
2003 
Salvarani 
(24) 
NA NA 
Typical symptoms 
Morning stiffness >1hour 
ESR >30 mm/hr 
CRP >0,5 mg/dl 
NA 
2004 
Caporali 
(20) 
NA NA 
Joint signs or symptoms 
(aching and stiffness of shoulder, 
hip girdle or both) 
ESR>30 mm/hr 
CRP>0,5 mg/dl 
NA 
2005 
Salvarani  
(30) 
NA NA 
Increase of symptoms 
ESR>30 mm/hr or CRP >0,5 mg/dl 
Good response after increase or 
restart GCs 
NA 
2007 
Catanoso 
(25) 
EULAR Response Criteria NA NA 
PMR-AS 
 
2007 
Hucthings 
(34) 
No pain or improvement of 
>50% in VAS girdles-pain,  
Morning stiffness<30 min, 
ESR <30 and CRP<1 mg/dl 
NA 
New symptoms and worsening lab 
tests requiring increase of GCs 
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2007 Leeb (33) NA NA  PMR-AS 
2007 
Salvarani  
(21) 
NA 
No symptoms 
or signs 
Normal ESR 
Increase of symptoms (aching and 
stiffness of shoulder, hip girdle or 
both) 
ESR>30 mm/hr or CRP >0,5 mg/dl 
Good response after increase or 
restart  GCs 
NA 
2008 Binard (35) NA NA NA PMR-AS 
2008 
Cimmino 
(36) 
NA NA 
Joint signs or symptoms 
(aching and stiffness of shoulder, 
hip girdle or both) 
ESR>30 mm/hr 
CRP >0,5 mg/dl 
NA 
2008 
Pulsateli 
(37) 
NA NA 
Recurrence of symptoms ESR>30 
mm/hr, 
CRP>0,5 mg/dl, 
Good response after restart or 
increase GCs 
NA 
2009 
Machioni  
(38) 
NA NA 
Reappearance of clinical 
manifestations 
ESR >30mm/hr 
CRP>0,5 mg/dl 
PMR-AS 
2010 Kreiner (22) NA NA NA PMR-AS 
2011 
Cimmino 
(26) 
NA 
≥70% 
improvement in 
clinical  
symptoms of 
PMR 
ESR and CRP 
normal 
1 month after 
start therapy 
NA NA 
2012 
Cleuziou 
(43) 
NA NA NA PMR-AS 
2013 
McCarthy 
(45) 
NA NA NA PMR-AS 
2014 
McCarthy 
(46) 
NA NA NA PMR-AS 
Outcome Measures in PMR 
 
 28 
Table 3: Summary definitions of Good Response, Remission, Relapse, Recurrence and 
Disease Activity used in different studies.  
ESR: CRP: C-Reactive Protein; Erythrocyte Sedimentation Rate; GCs: Glucocorticoids; NA: 
Not Applicable/Available; PMR-AS: Polymyalgia Rheumatica Activity Score; VAS: Visual 
Analogue Scale. Relapse (increase of symptoms/signs after remission or good response, in 
patients still receiving GCs) or recurrence (reappearance of symptoms and lab changes after 
remission or good response, following discontinuation of GCs). 
 
